- Botanix Pharmaceuticals (BOT) launches a canine atopic dermatitis program following ethics approval
- The company plans to enrol 45 dogs across three dermatology sites over 28 days, evaluating the effectiveness of both a high and low dose of BTX 1204A
- If the treatment is proven to be successful, Botanix believes it will drive licensing programs for animal health and support progression of a late-stage Phase 2b clinical study in humans with atopic dermatitis
- Meanwhile, the company said recruitment for its Phase 1b rosacea study is progressing to plan, despite COVID-19 restrictions
- Botanix Pharmaceuticals is up 2.99 per cent, trading at 6.9 cents at 2:15 pm AEST
Botanix Pharmaceuticals (BOT) has launched its canine atopic dermatitis program.
The clinical stage dermatology company’s BTX 1204A POC study in canines with atopic dermatitis is underway, following ethics approval and initiation of sites in Australia and New Zealand.
The company plans to enrol 45 dogs across three dermatology sites, which will evaluate the effectiveness of both a high and low dose of BTX 1204A. Each dog will be treated twice daily over a 28-day period.
The company said atopic dermatitis in canines and humans was very similar, both clinically and immunologically.
Botanix said previous studies indicated synthetic CBD, which is found in its treatment, addressessed multiple factors of disease pathology, inhibited itch and repaired skin barrier dysfunction.
If the treatment is proven successful, Botanix believes it will drive licensing programs for animal health and also support progression to a late-stage Phase 2b clinical study in humans with atopic dermatitis.
“Following encouraging results of our pilot study in Q2 CY2021, we are excited to now commence a larger BTX 1204A study in canines with atopic dermatitis,” Botanix President and Executive Chairman Vince Ippolito said.
“Given the similarity in disease between humans and canines, this study is an efficient and effective pathway to establishing the potential for a higher dose Permetrex formulation to demonstrate a new option for treating this significant disease challenge.”
Meanwhile, the company said recruitment for its Phase 1b rosacea study was progressing to plan, despite COVID-19 restrictions.
The rosacea study is a randomised, double blind, vehicle-controlled study in patients with moderate to severe papulopustular rosacea, investigating the safety and tolerability of two different concentrations of BTX 1702 and a placebo in adults, over an eight-week treatment period.
The study plans to enrol approximately 120 patients in dermatology clinical sites across Australia and New Zealand.
Botanix Pharmaceuticals was up 2.99 per cent, trading at 6.9 cents at 2:15 pm AEST.